Last $87.85 USD
Change Today -0.10 / -0.11%
Volume 1.0M
As of 2:18 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

hospira inc (HSP) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/5/15 - $88.04
52 Week Low
03/27/14 - $40.41
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for HOSPIRA INC (HSP)

hospira inc (HSP) Details

Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and market products worldwide. The company operates through Americas, EMEA, and APAC segments. It provides specialty injectable pharmaceuticals, which include approximately 200 injectable generic drugs in multiple dosages and formulations; and proprietary specialty injectables, such as Precedex, a proprietary drug for sedation. The company’s specialty injectable pharmaceuticals also comprise Biosimilars that include Retacrit, an EPO, which is primarily used in the treatment of anemia in dialysis and in certain oncology applications; Nivestim, a biosimilar filgrastim used for the treatment of low white blood cells in patients who have received a chemotherapeutic agent; and Inflectra, a biosimilar infliximab for the treatment of patients with autoimmune diseases, such as rheumatoid arthritis and inflammatory bowel disease. In addition, it offers medication management products, including infusion pumps and dedicated administration sets; Hospira MedNet safety software system and related services; software applications and devices that support point-of-care medication administration; gravity administration sets; and other device products. Further, the company provides intravenous solutions and nutritional products; and contract manufacturing services, as well as develops proprietary pharmaceutical products, such as Dyloject, a nonsteroidal anti-inflammatory drug analgesic. It serves hospitals and alternate site providers, such as clinics, home healthcare providers, and long-term care facilities. The company has collaborative arrangements with Bioceuticals Arzneimittel AG to license and market Retacrit; and Q Core Medical, Ltd to market and distribute Sapphire, a multi-therapy infusion system. Hospira, Inc. was founded in 2003 and is headquartered in Lake Forest, Illinois.

19,000 Employees
Last Reported Date: 02/12/15
Founded in 2003

hospira inc (HSP) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $1.0M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $464.7K
Senior Vice President of Operations
Total Annual Compensation: $432.5K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $444.6K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $429.8K
Compensation as of Fiscal Year 2013.

hospira inc (HSP) Key Developments

Hospira Launches Remicade Biosimilar Inflectra in Additional European Countries

Hospira announced that it is launching its Remicade biosimilar Inflectra in at least 10 new European markets, nearly doubling the product's presence on the continent. Inflectra (infliximab) is the first biosimilar monoclonal antibody to be marketed in Europe, will soon be available in Austria, Sweden, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands and Spain. Inflectra mimics Janssen's Remicade (infliximab), which treats inflammatory diseases such as psoriatic and rheumatoid arthritis, ankylosing spondylitis, adult and pediatric Crohn's disease, plaque psoriasis and ulcerative colitis.

Hospira Posts Interim Results from Patient Registry for Biosimilar Inflectra in IBD Treatment

Hospira (US) presented interim results from a patient registry study at the European Crohn's and Colitis Organisation's conference on inflammatory bowel diseases (IBDs) in Barcelona, Spain, on 19 February. The study looked at the firm's biosimilar version of Remicade (infliximab; Johnson & Johnson; J&J, US), Inflectra. The results from the ongoing independent, prospective study conducted in 90 patients across Hungary demonstrated comparable efficacy between Inflectra and Remicade for inducing and maintaining remission of Crohn's disease (CD) and ulcerative colitis (UC). So far, the patients who were treated with Inflectra for either CD (57) or UC (33) demonstrated reductions in disease activity at two and six weeks post treatment. Levels of C-reactive protein, a marker for inflammation, also declined in UC patients. With regards to safety and tolerability, Hospira reports that 4 of the 90 patients had an allergic reaction to Inflectra. The four patients have previously received anti- tumour necrosis factor treatment. The registry trial will continue to enrol patients and will follow CD patients for 108 weeks and UC patients for 54 weeks in order to assess the safety, adherence, long-term outcomes, and the cost of treatment with Inflectra.

Shareholders Foundation Announces Investor Lawsuit Against Acquisition of Hospira, Inc

The Shareholders Foundation Inc. announced that an investor, who currently holds shares of Hospira Inc., filed a lawsuit in effort to stop the proposed takeover of Hospira Inc. by Pfizer for $90 per share. The plaintiff alleges that the defendants breached their fiduciary duties owed to stockholders by agreeing to sell Hospira Inc. too cheaply via an unfair process to Pfizer Inc. On February 5, 2015, Pfizer Inc. and Hospira Inc. announced that they have entered into a merger agreement under which Pfizer will acquire Hospira for $90 a share in cash for a total enterprise value of approximately $17 billion. However, the plaintiff claims that the $90-offer is too low and undervalues Hospira Inc. In addition, the plaintiff claims that the process is also unfair to stockholders.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HSP:US $87.85 USD -0.10

HSP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CareFusion Corp $60.32 USD +0.065
Chugai Pharmaceutical Co Ltd ¥3,745 JPY +40.00
Cintas Corp $82.94 USD -0.83
UCB SA €68.50 EUR +0.26
Zimmer Holdings Inc $119.30 USD +0.54
View Industry Companies

Industry Analysis


Industry Average

Valuation HSP Industry Range
Price/Earnings 45.1x
Price/Sales 3.3x
Price/Book 4.5x
Price/Cash Flow 45.2x
TEV/Sales 2.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HOSPIRA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at